North America Blood Screening Market, By Products and Services (Reagents and Kits, Instruments, Software and Services), Technology (Nucleic Acid Test, Enzyme-Linked Immunosorbent Assay, Rapid Tests, Western Blot Assay, Next-Generation Sequencing and Others), Disease Type (Respiratory Diseases, Diabetes Mellitus, Oncology, Cholesterol, HIV/AIDS, Cold and Flu, Infectious Diseases and Others), End User (Diagnostic Centers, Blood Bank, Hospitals, Clinics and Ambulatory Surgical Centers), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2029
Market Analysis and Insights of Blood Screening Market
Data Bridge Market Research analyses that the blood screening market will exhibit a CAGR of around 10.80% for the forecast period of 2022 to 2029. Rising prevalence of chronic disorders, increased focus on research and development proficiencies in regards to medical devices and on the adoption of advanced healthcare technologies, growth in the awareness amongst the patients regarding the donation of blood to a serious patient and rising expenditure for the development of healthcare infrastructure especially in the developing economies are the major factors attributable to the growth of blood screening market.
From the name itself, it is clear that blood screening is a medical process of screening and testing different blood samples for various infections and contaminations such as HIV1, HIV2, HBV, and HCV. Blood screening is done to diagnose the disease and its cause.
Upsurge in the research and development proficiencies by the life sciences industry is one of the major factors fostering the growth of the market. Growth in the occurrences of new form of pathogens and need for accurate and efficient diagnosis at early stages are other market growth determinants. Rising westernization and rising medical tourism are other important factors that will further generate lucrative market growth opportunities.
However, improper and unfavourable reimbursement scenario in the developing and underdeveloped economies will derail the market growth rate. Also, high costs associated with research and development proficiencies and with the sampling of blood will further pose challenges for the market. Dearth of skilled professionals in the backward economies will also hamper the market growth rate.
This blood screening market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on blood screening market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
North America Blood Screening Market Scope and Market Size
The blood screening market is segmented on the basis of products and services, technology, disease type and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of products and services segment, the blood screening market is segmented into reagents and kits, instruments and software and services. Reagents and kits are further sub-segmented into NAT reagents and kits, ELISA reagents and kits others as well. NAT reagents is further sub-segmented into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions also labelling and detection reagents. ELISA reagents & kits is further sub-segmented into immunosorbents, controls, conjugates (antigen or antibody-conjugated enzyme), substrates (of enzymes) also sample diluents and wash solutions. Instruments segment is further segmented into instruments, product types and instruments and purchase type.
- On the basis of technology, the blood screening market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test is further sub-segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) is further segmented into ELISA market, by platform, ELISA market, by generation. ELISA market, by platform is further sub-segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA) and colorimetric immunoassay (CI). ELISA market, by generation is further segmented into first-generation ELISA, second-generation ELISA, third-generation ELISA and fourth-generation and above.
- On the basis of disease type segment, the blood screening market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold and flu, infectious diseases and others.
- The end user segment in the blood screening market is segmented into diagnostic centers, blood bank, hospitals, clinics and ambulatory surgical centers.
Blood Screening Market Country Level Analysis
The blood screening market is analysed and market size insights and trends are provided by country, products and services, technology, disease type and end user as referenced above.
The countries covered in the blood screening market report are U.S., Canada and Mexico.
U.S. in North America region dominates the blood screening market owing to rise in awareness about blood donation and the presence of high-quality infrastructure for hospitals and clinical laboratories, and the presence of major market players in the country.
The country section of the blood screening market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The blood screening market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for charge-coupled device (CCD) imagers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the blood screening market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Blood Screening Market Share Analysis
The blood screening market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to blood screening market.
Some of the major players operating in the blood screening market report are Enzo Biochem Inc., Meridian Bioscience, Inc., BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., BioMérieux SA, Beckman Coulter, Inc., Abbott, F. Hoffmann-La Roche Ltd, Cepheid, GRIFOLS INTERNATIONAL, S.A., Siemens, Ortho Clinical Diagnostics, Immucor, Inc., Hologic Inc., DiaSorin, GFE, Trinity Biotech, and Merck KGaA among others.
SKU-